ARTICLE | Cover Story
Melanoma's hidden act
October 25, 2012 7:00 AM UTC
Researchers at the University of Bonn and the Johannes Gutenberg University Mainz have shown that melanoma cells can acquire resistance to adoptive T cell transfer therapies by dedifferentiating themselves to hide antigens.1 The group now is trying to circumvent this resistance mechanism and thinks doing so could improve treatment responses for current T cell therapy protocols.
Adoptive T cell transfer is one of three immunotherapy-based strategies used to treat metastatic melanomas and typically is used in patients for whom standard treatments have failed...